Much of this was because of a fairly wide bottom-line miss in Casella's second quarter, the results of which were published after market close Thursday. That drop was discouraging enough, but it was exacerbated by the fact that analysts were expecting far better from the company. On average, they were modeling $0.33 per share for bottom-line profitability, although they underestimated revenue with a collective $454 million projection. Although revenue was notably higher in the second quarter, net income cam ...

Pilgrim's Pride (PPC 1.20%) reported its financial results for the second quarter of fiscal 2025 on July 30, 2025. The company exceeded analyst forecasts for both GAAP revenue and non-GAAP EPS, posting non-GAAP earnings per share (EPS) of $1.70, which surpassed the non-GAAP consensus estimate of $1.57. Revenue (GAAP) reached $4.76 billion, topping GAAP estimates of $4.62 billion, and increasing from $4.56 billion in the prior-year quarter (GAAP, Q2 FY2024). Management approved a special $500 million dividen ...

Dolby Laboratories (DLB -6.84%), a globally recognized leader in audio and visual technology, reported earnings for Q3 FY2025 on July 31, 2025. The company posted GAAP revenue of $315.5 million, ahead of the analyst consensus of $305.2 million (GAAP) and up from $288.8 million (GAAP) in Q3 FY2024. Non-GAAP earnings per share reached $0.78, topping non-GAAP estimates of $0.71. The quarter also saw higher GAAP operating and net income on a year-over-year basis. This result demonstrates robust performance desp ...

A solid quarterly earnings report reverberated though the pundit community that day.A bellwether stock in the lately rather up-and-down pharmaceutical sector, AbbVie (ABBV 3.28%) finished the trading week in style. The company's shares closed more than 3% higher in price thanks in no small part to a clutch of post-earnings analyst price-target increases. With that performance, Abbvie crushed the S&P 500 index, which dived by 1.6% on the day. A bullish stampedeAs typically happens when a publicly traded comp ...

Amicus Therapeutics (FOLD 5.51%), a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP earnings. The company reported GAAP revenue of $154.7 million, up from $126.7 million (GAAP) a year earlier and $8.0 million ahead of the $146.7 million analyst target. Non-GAAP earnings per share came in at $0.01, far better than the non-GAAP EPS estimate of –$0.12. The quarter showed solid commercial momentum for the co ...

PROS Holdings (PRO -5.10%), a provider of artificial intelligence-powered pricing and revenue optimization software for global enterprises, reported results for Q2 2025 on July 31, 2025 that surpassed Wall Street estimates both on revenue and earnings. The company delivered GAAP revenue of $88.7 million against an estimate of $87.66 million (GAAP), with non-GAAP earnings per share (EPS) of $0.13—more than double the consensus forecast of $0.06 per share (non-GAAP). Subscription revenue rose by 12% to $73.3 ...

Bloom had a great quarter, but anything less than perfection caused a round of profit taking.Shares of on-premises electricity generator provider Bloom Energy (BE -1.46%) plunged initially today, down 13% at one point, before recovering to a 1.4% decline as of 3:26 p.m. ET.Bloom reported second-quarter earnings last night, beating revenue estimates but missing the mark on the adjusted (non-GAAP) earnings-per-share (EPS) line. Of course, Bloom is a growth stock, so the top line matters more. However, since t ...

Investors were uncomfortable with the unexpected resignation of Rakesh Gangwal.Southwest Airlines (LUV -3.65%) announced a sudden change in its corporate governance, and that shift rattled some investors. The airline's stock price took an almost 4% hit on Friday during a session when the S&P 500 index closed down a relatively modest 1.6%.New day, new chairJust after market close on Thursday, Southwest announced that Rakesh Gangwal had resigned from his position as chair of the company's board of directors. ...

Fortune Brands Innovations (FBIN 2.37%), a leading provider of branded home and security products, released its earnings report for the second quarter of fiscal 2025 on July 31, 2025. The quarter’s most notable news: while both earnings (non-GAAP) and revenue (GAAP) exceeded analyst forecasts, results fell from the prior year on key measures. Non-GAAP earnings per share (EPS) came in at $1.00, beating the $0.96 analyst consensus (Non-GAAP) EPS, while revenue (GAAP) reached $1.20 billion, besting the $1.19 b ...

Core Insights - Cigna Group reported strong second-quarter earnings for 2025, with revenue reaching $67.2 billion and adjusted diluted EPS at $7.20, surpassing analyst expectations [1][2] - The company experienced broad-based revenue growth driven by its Evernorth Health Services platform, although profit margins moderated due to shifts in customer mix following the divestiture of Medicare-related businesses [1][5] Financial Performance - Adjusted diluted EPS increased by 7.1% year-over-year from $6.72 to $7.20, while revenue grew by 11.1% from $60.5 billion to $67.2 billion [2] - Net income (GAAP) for the quarter was reported at $1.53 billion [5] - The adjusted SG&A expense ratio improved to 4.9% from 6.0%, reflecting enhanced cost efficiency [9] Business Segments - Evernorth Health Services was the primary growth driver, with adjusted revenues increasing by 17% to $57.8 billion and pre-tax adjusted income rising by 5% to $1.70 billion [6] - Cigna Healthcare saw an 18% decline in adjusted revenues year-over-year due to the divestiture of Medicare businesses, but adjusted revenue excluding divestitures rose by 7% [7] Customer Base and Trends - Total customer relationships stood at 182.2 million, with a 2% increase excluding the impact of the HCSC transaction [8] - Pharmacy customer counts grew by 3% to 121.9 million, while the medical customer base declined to 18.0 million [8] Strategic Focus and Innovation - Cigna is focused on digital innovation and operational efficiency, investing in AI and customer experience [4] - The company expanded digital engagement initiatives aimed at managing costs and improving patient outcomes, particularly for high-cost drugs [10] Future Guidance - Cigna reaffirmed its guidance for FY2025, projecting adjusted income from operations of at least $29.60 per share, with segment expectations for Evernorth and Cigna Healthcare set at $7.2 billion and $4.125 billion in pre-tax adjusted income, respectively [12] - The company anticipates a medical care ratio in Cigna Healthcare of 83.2% to 84.2% for FY2025 [12]